ArticleScientific reports2024

Soluble programmed death ligand 1 as prognostic biomarker in non-small cell lung cancer patients receiving nivolumab, pembrolizumab or atezolizumab therapy.

Sinne Søberg Brun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.